Truist Financial analyst Joon Lee has maintained their bullish stance on JAZZ stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joon Lee has given his Buy rating due to a combination of factors including the promising potential of Jazz Pharmaceuticals’ drug, Ziihera. The positive Phase 3 HERIZON-GEA-01 topline results have significantly reduced the risk associated with Ziihera in first-line HER2+ gastric and esophageal adenocarcinoma, justifying an increase in the probability of success and a subsequent upward revision in market penetration estimates.
Moreover, Ziihera’s demonstrated efficacy in the PD-L1 negative subgroup sets it apart from other programs that have not succeeded in this area. The drug’s potential to address a broad range of HER2+ cancers, coupled with its premium pricing and large addressable market, positions it for substantial commercial success. The intellectual property protection through the early 2030s further strengthens its strategic outlook, supporting the decision to reiterate a strong Buy rating and raise the price target to $220.
In another report released today, Robert W. Baird also maintained a Buy rating on the stock with a $209.00 price target.